Efficacy and safety of enoxaparin in combination with and without GP IIb/IIIa inhibitors in unselected patients with ST segment elevation myocardial infarction treated with primary percutaneous coronary intervention

EuroIntervention

Volumn 4, Issue 4, 2009, Pages 524-528

  Zeymer, Uwe ^a,b   Gitt, Anselm ^a,b   Zahn, Ralf ^a   Jünger, Claus ^b   Bauer, Timm ^a   Heer, Tobias ^a   Koeth, Oliver ^a   Senges, Jochen ^b  

^a KLINIKUM LUDWIGSHAFEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Acute myocardial infarction; Enoxaparin; Heparin; Primary PCI

Indexed keywords

ANTITHROMBOCYTIC AGENT; ENOXAPARIN; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; HEPARIN;

ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG COMBINATION; GERMANY; HEART INFARCTION; HUMAN; MORTALITY; MULTICENTER STUDY; RECURRENT DISEASE; REGISTER; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; ENOXAPARIN; FIBRINOLYTIC AGENTS; GERMANY; HEMORRHAGE; HEPARIN; HOSPITAL MORTALITY; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 63049140130     PISSN: 1774024X     EISSN: 19696213     Source Type: Journal    
DOI: 10.4244/EIJV4I4A88     Document Type: Article

References (18)

1. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FW, Wijns W; Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Management of acute myocardial infarction in patients presenting with STsegment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2003 24: 28-66
2. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, Alpert JS, Anderson JL, Faxon DP, Fuster V, Gibbons RJ, Gregoratos G, Halperin JL, Hiratzka LF, Hunt SA, Jacobs AK; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004 110:e82-292.
3. Hirsh J. Heparin. N Engl J Med 1991; 324: 565-1574.
4. Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM, Dalen JE. Heparin and low molecular weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest 2001; 119: 64S-94S.
5. Baird SH, Menown IB, Mcbride SJ, Trouton TG, Wilson C. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J 2002; 23: 627-32.
6. Ross AM, Molhoek P, Lundergan C, Knudtson M, Draoui Y, Regalado L, Le Louer V, Bigonzi F, Schwartz W, de Jong E, Coyne K; HART II Investigators. Randomized comparison of enoxaparin, a low-molecularweight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104: 648-52.
7. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-13.
8. Wallentin L, Goldstein P, Armstrong PW, Granger CB, Adgey AA, Arntz HR, Bogaerts K, Danays T, Lindahl B, Mäkijärvi M, Verheugt F, Van de Werf F. Efficacy and safety of tenecteplase in combination with the lowmolecular- weight heparin enoxaparin in the prehospital setting. The ASSENT-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003; 108: 135-142.
9. Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 2005; 112: 3855-67.
10. Antman EM, Morrow DA, McCabe CH, Jiang F, White HD, Fox KA, Sharma D, Chew P, Braunwald E; ExTRACT-TIMI 25 Investigators. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am Heart J 2005; 149: 217-26.
11. Antman EM, Morrow DA, McCabe CH, Murphy SA, Ruda M, Sadowski Z, Budaj A, López-Sendón JL, Guneri S, Jiang F, White HD, Fox KA, Braunwald E; ExTRACT-TIMI 25 Investigators.Enoxaparin versus unfractionated heparin with thrombolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354: 1477-1488.
12. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, Bode C, Chiariello M, King SB 3rd, Harrington RA, Desmet WJ, Macaya C, Steinhubl SR; STEEPLE Investigators. Enoxaparin versus unfractionated heparin in elecetive percutaneous coronary intervention. N Engl J Med 2006; 355; 1006-1017.
13. Gibson CM, Murphy SA, Montalescot G, Morrow DA, Ardissino D, Cohen M, Gulba DC, Kracoff OH, Lewis BS, Roguin N, Antman EM, Braunwald E; ExTRACT-TIMI 25 Investigators.. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007; 49: 2238-2246.
14. Zeymer U, Senges J. Qualitätsregister in der Kardiologie. Bundesgesundheitsbl-Gesundheitsforsch-Gesundheitsschutz 2004; 47: 533-539.
15. Morrow DA, Antman EM, Charlesworth A, Cairns R, Murphy SA, de Lemos JA, Giugliano RP, McCabe CH, Braunwald E. TIMI Risk Score for ST-elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation. Circulation 2000;102: 2031.
16. Welsh RC, Gordon P, Westerhout CM, Buller CE, O'Neill B, Armstrong PW. A novel enoxaparin regimen for ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: intravenous but not subcutaneous enoxaparin achieves adequate Anti-Xa levels. J Am Coll Cardiol 2006; 47, Supplement A, 228A (Abstract).
17. The ADVANCE MI Investigators. Facilitated percutaneous coronary intervention for acute ST-segment elevation myocardial infarction: results from the prematurely terminated Adressing the Value of facilitated Angioplasty after combination therapy or Eptifibatide monotherapy in acute Myocardial infarction trial (ADVANCE MI) trial. Am Heart J 2005; 150: 116-122.
18. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A; Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in highrisk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 2003; 107: 238-244.